Antramups

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antramups

What is Antramups?

Antramups is a medication that belongs to a group of drugs known as proton pump inhibitors (PPIs). It contains the active substance omeprazole, which is formulated to reduce the amount of acid produced by the stomach.

Mechanism of Action

The stomach naturally produces acid to help digest food and kill bacteria. However, an overproduction of this acid can lead to irritation of the stomach lining and the esophagus. Antramups works by targeting the gastric proton pumps—specific enzymes found in the lining of the stomach wall that are responsible for the final stage of acid secretion. By inhibiting these pumps, the medication effectively lowers the acidity levels in the digestive tract.

Clinical Applications

This medication is primarily used to manage conditions related to gastric acid. These include:

  • Gastroesophageal Reflux Disease (GERD): A condition where acid from the stomach escapes into the esophagus, causing discomfort or inflammation.
  • Ulcers: The treatment and prevention of ulcers in the upper part of the intestine (duodenal ulcers) or the stomach (gastric ulcers).
  • Zollinger-Ellison Syndrome: A rare condition where the stomach produces excessive amounts of acid due to a growth in the pancreas or small intestine.
  • Antibiotic Support: In some cases, it is used in combination with antibiotics to treat infections caused by Helicobacter pylori bacteria, which are a common cause of stomach ulcers.

Physical Characteristics

Antramups is typically available in the form of tablets or capsules designed for oral administration. Some formulations may be designed as gastro-resistant, meaning the medication is protected from stomach acid so that it can be absorbed properly in the intestine.

Regulatory References

  1. Omeprazole - StatPearls - NCBI Bookshelf - NIH
  2. DailyMed - NIH

What side effects are possible with Antramups?

Possible side effects and safety information

The safety profile for the active ingredient in Antramups (omeprazole) outlines adverse reactions grouped by both frequency and the physiological system affected, consistent with regulatory classifications from government health authorities.

Documented Adverse Reactions and Frequencies

Adverse reactions classified as Common (occurring in 1 to 10 out of 100 people) primarily involve the gastrointestinal system, including abdominal pain, constipation, diarrhoea, flatulence, nausea, vomiting, and headache. Uncommon effects (1 to 10 out of 1,000 people) include dizziness, insomnia, and increases in liver enzymes, as well as skin reactions like rash and pruritus.

Rare and Very Rare effects involve more systems, such as blood disorders (leukopenia, thrombocytopenia, agranulocytosis), severe hypersensitivity reactions (anaphylactic shock), psychiatric disturbances (confusion, depression), and severe skin disorders like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Patterns Related to Exposure

Certain effects are noted by regulatory labels to be associated with prolonged use. Long-term therapy may be linked to an increased risk of bone fracture of the hip, wrist, or spine. Additionally, extended treatment may necessitate consideration of potential Hypomagnesaemia (low magnesium levels) and Vitamin B12 deficiency. The development of benign fundic gland polyps is also noted with prolonged use.

Regulatory Safety Constraints

The medicine is contraindicated in individuals with known hypersensitivity to omeprazole or any substituted benzimidazoles. Regulatory documents state that a symptomatic response to treatment does not exclude the possibility of a gastric malignancy, and this condition must be ruled out. Furthermore, caution is noted in patients with pre-existing severe hepatic impairment, where rare cases of encephalopathy have been documented.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Omeprazole (Antramups) overdose details the recognized signs and symptoms and mandates specific emergency actions.

Documented Overdose Manifestations

Overdose presentations documented in official product labeling generally affect the gastrointestinal and central nervous systems. Clinical signs can include headache, nausea, vomiting, diarrhea, abdominal pain, drowsiness (somnolence), and blurred vision. Cardiovascular effects such as tachycardia (abnormally fast heart rate) have also been reported.


Emergency Actions and Management

Official guidance requires that users seek immediate medical attention and contact a Poison Control Center right away in the event of any suspected overdose. While Omeprazole overdose is often described as rarely serious, prompt evaluation by a healthcare provider is mandatory. No specific antidote is known for Omeprazole, and the substance is not readily removed by hemodialysis because it is highly protein-bound.

Management is strictly symptomatic and supportive. This official approach may include continuous monitoring of vital signs and, if appropriate, procedures such as gastric lavage or the administration of activated charcoal to reduce drug absorption.

Therapeutic Uses of Antramups

Main uses of Antramups

Antramups is a medication primarily used to manage conditions related to excessive stomach acid production. It belongs to a class of drugs known as proton pump inhibitors (PPIs), which work by reducing the amount of acid produced by the glands in the lining of the stomach.

Gastroesophageal Reflux Disease (GERD)

One of the primary uses of this medication is the treatment of gastroesophageal reflux disease. This condition occurs when stomach acid frequently flows back into the tube connecting the mouth and stomach (esophagus). This backwash can irritate the lining of the esophagus, leading to symptoms such as heartburn and acid regurgitation.

Gastric and Duodenal Ulcers

Antramups is indicated for the healing and prevention of ulcers in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). It helps in the recovery process by maintaining a less acidic environment, allowing the mucosal lining to heal. It is also used in combination with specific antibiotics to eliminate Helicobacter pylori, a bacterium often associated with the recurrence of these ulcers.

Zollinger-Ellison Syndrome

This medication is used to manage Zollinger-Ellison syndrome, a rare condition in which one or more tumors form in the pancreas or the upper part of the small intestine. These tumors secrete large amounts of the hormone gastrin, which causes the stomach to produce too much acid, leading to severe peptic ulcers.

Protection During NSAID Therapy

For patients requiring long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs), Antramups may be used to reduce the risk of developing stomach ulcers associated with these medications.

Benefits of treatment

Symptom Relief

The primary benefit for most patients is the significant reduction of symptoms such as persistent heartburn, difficulty swallowing, and chest pain associated with acid reflux. By lowering acid levels, the medication helps alleviate the discomfort caused by acid irritation.

Healing of the Esophagus and Mucosa

In cases where acid reflux has caused inflammation or erosions in the esophagus (erosive esophagitis), reducing acid production allows the damaged tissue time to heal. Similarly, it facilitates the healing of active ulcers in the digestive tract.

Prevention of Complications

By effectively managing acid production, the medication helps prevent long-term complications associated with chronic acid exposure, such as strictures (narrowing of the esophagus) or Barrett's esophagus.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Antramups eligibility is strictly defined by regulatory documentation based on absolute prohibitions, age criteria, and specific health conditions. The medicine is generally approved for use in adults and in children aged one year or older who weigh at least 10 kg for specific indications. Older adults are also eligible and typically do not require dose adjustment.

Use of Antramups is absolutely contraindicated in patients with a known hypersensitivity to omeprazole, related substituted benzimidazoles, or any formulation excipients. It is also prohibited for use in patients concomitantly receiving the antiviral drug nelfinavir.

For pediatric patients, safety and efficacy are not established in infants younger than one month of age. Patients with impaired renal function do not require dose adjustment, but those with impaired hepatic function may require a lower daily dose. Use during pregnancy is permitted only when the expected benefit justifies the potential risk. Use during lactation is not recommended as the substance is excreted into human milk. Specific formulations may also be restricted for patients with rare hereditary problems, such as galactose intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Omeprazole (the active ingredient in Antramups) primarily through two pharmacokinetic mechanisms: the inhibition of certain metabolic enzymes and the drug’s acid-suppressing effect.

Documented Interaction Patterns

Omeprazole is a documented inhibitor of the enzyme CYP2C19. Co-administration with drugs metabolized by this pathway, such as Cilostazol or Diazepam, may lead to a prolonged elimination and increased systemic exposure of the partner medicine, as formally stated in prescribing information. The same mechanism requires monitoring when taken with Warfarin or Phenytoin.

Antramups’ sustained reduction of gastric acid alters intragastric pH. This effect reduces the absorption of medicines requiring an acidic environment for uptake, including Ketoconazole, Iron Salts, Ampicillin Esters, and certain antiretrovirals like Nelfinavir and Atazanavir.

Official Restrictions and Constraints

Official labeling describes several specific restrictions based on interaction risk:

  • Contraindicated/Avoid Use: Co-administration with the antiplatelet agent Clopidogrel is discouraged because it reduces the drug’s effectiveness. Regulatory bodies confirm that separating the administration time will not prevent this interaction. Similarly, use with Rifampin and the herbal product St. John’s Wort is generally avoided.
  • Exposure Monitoring: Co-administration with Digoxin or the immunosuppressant Tacrolimus may increase their respective plasma levels, requiring monitoring.
  • Diagnostic Interference: Omeprazole treatment interferes with the measurement of Chromogranin A (CgA). Temporary cessation of Antramups is required prior to this specific diagnostic test.

Mechanism of Action

Antramups is a medication that modulates key pathways within the stomach lining to exert a targeted and sustained effect on acid production. Its action is centered on inhibiting the final step of acid secretion, resulting in a significant and prolonged alteration in the stomach's overall acidity.

Directly Inhibiting the Proton Pump

This mechanism describes the core molecular action: Antramups targets the H^+/ K^+-ATPase enzyme (the Proton Pump) within the stomach's acid-producing parietal cells. After being activated by the acidic environment, the drug acts as an irreversible inhibitor, permanently binding to this enzyme. This domain is central because it directly blocks the final common pathway for hydrochloric acid secretion, resulting in a pronounced alteration in gastric pH.


Sustained Regulation of Gastric Secretion

This domain covers the downstream effects and the duration of the drug's action. Because Antramups forms an irreversible bond with the pump, the effect persists until the body synthesizes entirely new, functional enzyme units. The mechanistic effect is dependent on the inhibition of a sufficient number of active pumps, which is established progressively during use. This sustained reduction in acidity results in a modulated state within the targeted physiological pathway, leading to an environment where the concentration of digestive acid is lowered.

Dosage and Administration Information

Official Administration Guidelines

Antramups is officially administered via the oral route as a gastro-resistant tablet or capsule. The preparation is designed to be swallowed whole using water, and guidelines strictly prohibit chewing, crushing, or breaking the tablets, as this compromises the essential gastro-resistant coating. The medication is typically taken once daily in the morning, before a meal, to standardize its administration relative to acid production.

Official dosing is standardized across several strengths, including 10 mg, 20 mg, and 40 mg. For initial treatment of conditions like esophagitis or ulcers, standard adult doses often range from 20 mg to 40 mg once daily, usually for a short-term course of four to eight weeks. In contrast, certain hypersecretory conditions, such as Zollinger-Ellison Syndrome, require long-term use and may involve initial doses of 60 mg daily, which can be increased and must be administered in divided doses when the total exceeds 80 mg per day.

Dosing requires modification only for specific patient populations. No dose change is specified for older adults or those with renal impairment. However, a dose reduction to 10 mg or 20 mg daily is stated for individuals with severe hepatic impairment. If a dose is missed, instructions advise taking it promptly unless the next scheduled dose is due, in which case the missed dose must be skipped; double-dosing is explicitly prohibited.

Recent Clinical Evidence

Research evidence / Overview of studies for Antramups

Evidence for Use in Symptomatic Acid Reflux (GERD) and Esophagitis

Research exploring the drug's use in conditions characterized by episodic or acute manifestations, such as symptomatic acid reflux (Gastroesophageal Reflux Disease or GERD) and the management of erosive esophagitis, primarily utilizes short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were used in research exploring how symptoms change over time. Specifically, researchers measured patient-reported outcomes describing perceived discomfort, such as heartburn and acid regurgitation, and also utilized objective measurements like the assessment of endoscopic healing rates for irritated tissue in the esophagus. The evidence contributes to the broader evidence landscape by providing insight into short-term changes.

However, follow-up durations for many of these initial studies were limited to the healing phase. Research explored whether the compound was evaluated in conditions involving periods of heightened symptoms; however, the body of comparative evidence across the drug class remains somewhat mixed, limiting clear insight into any variations between agents.

Evidence for Use in Peptic Ulcer Disease and Hypersecretory Conditions

The research base also includes studies where omeprazole was evaluated in trials addressing duodenal and gastric ulcers, as well as rare, chronic conditions like Zollinger-Ellison Syndrome (ZES). For ulcers, studies explored outcomes related to physical discomfort, and the primary focus was on the measurement of endoscopic ulcer healing rates over short-term periods. The research examined temporary physiological imbalance related to gastric acid levels. For the rare hypersecretory conditions like ZES, the drug was studied for its ability to maintain control over acid output, with evidence derived mainly from long-term, continuous observational settings rather than large-scale RCTs.

Data from the short-term trials indicate patterns related to the monitored ulcer outcomes in the observed populations. Research describes the findings observed regarding ulcer recurrence when omeprazole was administered as part of an antibiotic regimen for H. pylori. In chronic hypersecretory conditions, long-term observational research describes the sustained control of acid output. However, evidence derived from settings with varying symptom burdens for rare conditions means that sample sizes were modest.

Recognized Gaps and Areas of Research Uncertainty

Research highlights several gaps and uncertainties across the evidence landscape. Firstly, long-term effects are not fully established; controlled evidence beyond intermediate follow-up durations was limited. Secondly, evidence quality varies across studies; data regarding comparative findings against other agents remains insufficient or findings were mixed. Finally, for rare indications like ZES, sample sizes were modest, and research does not determine whether an individual will respond similarly to group patterns. These research limitations highlight where more data are still emerging and where certainty remains low.

Key Studies & References

  1. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs (Systematic Review)
  2. Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders (Review Article of RCTs)
  3. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population (Comparative RCT)

Frequently Asked Questions (FAQ)

Common questions about Antramups (FAQ)

Q: How long does the effect of one dose of Antramups typically last?

A: The inhibitory effects of Antramups on acid production begin quickly. Official sources describe that the primary effect on acid secretion can persist for approximately 72 hours after a single dose. However, the body’s full return to baseline acid activity usually takes between 3 to 5 days as new acid pumps are generated.


Q: Is it common to feel a little dizzy or tired when starting Antramups?

A: Regulatory documents list some central nervous system effects, such as dizziness and insomnia, as uncommon side effects. Headache is listed as a common effect. Official information does not specifically describe a pattern where these effects are more likely to occur only during the initial days of starting the medication.


Q: What types of foods or drinks might interact with Antramups?

A: Official regulatory information specifies that there are no known interactions with specific foods or beverages. The regulatory documents note that the medication is typically administered before a meal to standardize how it is absorbed relative to the body's acid production cycle.


Q: What information is available about taking Antramups during pregnancy?

A: Epidemiologic studies reviewed by regulatory agencies indicate that the risk of major malformations is unlikely. Official guidance states that the drug should only be used during pregnancy if the potential benefit justifies the potential risks.


Q: What information is available about driving or operating machinery while taking Antramups?

A: Taking Antramups generally will not affect the ability to drive or use machinery. However, regulatory documents state that if a patient experiences side effects such as dizziness or vision problems, they should wait until the effects have passed before performing tasks that require concentration.


Q: Can Antramups cause changes in mood or sleep patterns?

A: Official product information notes insomnia (difficulty sleeping) as an uncommon adverse reaction. More rarely, psychiatric disturbances, including confusion and depression, have also been reported in regulatory documents.


Q: Are there currently ongoing clinical trials or studies related to Antramups?

A: Regulatory bodies frequently refer to both past and ongoing clinical studies as part of their comprehensive review processes. Information about currently recruiting or active trials for the drug's active ingredient can typically be found on government-managed registries, such as the NIH Clinical Trials Register.


Q: Does Antramups need to be kept at a specific room temperature or refrigerated?

A: Official storage instructions state that the drug should be stored at room temperature, specifically below 25 C (77 F). It is explicitly noted that the medication does not require refrigeration.


Q: Does Antramups interact with alcohol consumption?

A: According to official regulatory documents, there are no known drug interactions between the active ingredient (omeprazole) and alcohol (ethanol).


Q: Can Antramups be crushed or split if a patient has trouble swallowing?

A: No. The official administration guidelines are clear that the gastro-resistant tablet or capsule must be swallowed whole and should not be chewed, crushed, or broken. This is necessary because damaging the enteric coating compromises the medication's intended delayed-release function.


Q: Are there specific symptoms that require immediate medical attention while taking Antramups?

A: Yes, official regulatory documents list severe, rare reactions that require immediate medical attention. These include signs of a severe allergic reaction (such as difficulty breathing, swelling of the face, or hives) or severe skin reactions (like extensive blistering, peeling, or reddening of the skin).


Q: Is Antramups considered a common type of medication?

A: Antramups contains an active ingredient that belongs to the Proton Pump Inhibitor (PPI) class of drugs. Official documents confirm its active ingredient was the first in this class to be approved, and the PPI class is now widely utilized in healthcare to address conditions related to excessive stomach acid.


Q: How is Antramups different from other medicines that treat similar symptoms?

A: The difference in Antramups is primarily in its design. The medication uses the Multiple-Unit Pellet System (MUPS) technology, which delivers the active ingredient as numerous small pellets. This proprietary system is designed to provide a uniform gastro-resistant, delayed-release profile.


Q: What happens if I miss a scheduled time to take Antramups?

A: If a dose is missed, official instructions advise taking it as soon as it is remembered, unless the time for the next scheduled dose is nearly due. If it is close to the next dose, the missed one must be skipped. Regulatory documents explicitly prohibit double-dosing to make up for a missed dose.


Q: Is Antramups available in a generic version?

A: Yes. The active ingredient in Antramups, Omeprazole, has been available in generic versions for a long time. This is confirmed by its listing as a Reference Listed Drug (RLD) in regulatory databases used by the FDA.


Q: What is the difference between a generic and a brand name version of Antramups?

A: Regulatory requirements mandate that generic versions must contain the exact same active ingredient, be of the identical dosage and strength, and demonstrate bioequivalence to the brand-name product. The only elements permitted to differ are typically inactive ingredients.


Q: What is the chance of having an allergic reaction to Antramups?

A: Official product information lists severe hypersensitivity reactions, including anaphylactic shock, as Rare or Very Rare. This means they occur in less than 1 out of every 1,000 patients who take the medicine.


Q: What is the official guidance on informing healthcare providers, like a dentist, about taking Antramups?

A: Official labeling indicates that Antramups can interfere with certain diagnostic investigations, such as specific blood tests. Therefore, official guidance emphasizes that patients should inform their healthcare providers of all medications being taken, especially before diagnostic investigations.


Q: What should be done if I suspect an interaction between Antramups and another product?

A: Regulatory documents describe that if symptoms of a severe reaction (like swelling or breathing issues) occur, the drug should be stopped, and emergency medical care is required. For non-emergent concerns, patients are described as needing to inform their healthcare provider.

How should Antramups be stored and disposed of?

Official Storage and Disposal Requirements

Antramups (Omeprazole MUPS tablets) must be stored under specific environmental constraints to maintain the integrity of the gastro-resistant formulation and the stability of the active drug.

Classification Regulatory Requirement
Storage Temperature Store at room temperature, typically below 25 C (77 F), and do not freeze.
Protection Keep the product in the original container to protect it from moisture and light.
Child Safety Mandatory storage requirement is to keep the medicine out of the sight and reach of children.

Unused, expired, or unwanted medicine must be handled as pharmaceutical waste. Official regulatory instructions prohibit disposal of Antramups via the wastewater system (e.g., flushing) or ordinary household trash. The product must be disposed of according to local regulations, typically through pharmacy take-back or designated collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antramups found in:

A-Z Index: